

processes, safety and/or other matters that could affect the availability or commercial potential of any such vaccine candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding any such vaccine candidates and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.Pfizer.com.

BioNTech Media Relations

Jasmina Alatovic
Senior Manager Global External Communications
Tel: +49 (0)6131 9084 7640 or +49 (0)151 1978 1385
E-mail: media@biontech.de

BioNTech Investor Relations

Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
Tel: +49 (0)6131 9084 1074
E-mail: investors@biontech.de

Pfizer Media Relations

Amy Rose (U.S.)
+1 (212) 733-7410
amy.rose@pfizer.com

Lisa O'Neill (UK)

+44 7929339560
lisa.o'neill@pfizer.com

Pfizer Investor Relations

Ryan Crowe
+1 (212) 733-8160
ryan.crowe@pfizer.com